pmc logo image
Logo of cmajCMAJ Information for AuthorsCMAJ Home Page

Formats:

CMAJ. 1996 January 15; 154(2): 165–170.
PMCID: PMC1488147
Abortion induced with methotrexate and misoprostol.
E R Wiebe
Department of Family Practice, University of British Columbia, Vancouver.
Abstract
OBJECTIVE: To determine the outcome and side effects of a new drug protocol to induce abortion. DESIGN: Case series. SETTING: An urban primary care practice. PATIENTS: One hundred consecutive patients who requested elective termination of pregnancies of less than 8 weeks' gestation. INTERVENTION: Subjects received methotrexate (50 mg/m2 body surface area, administered intramuscularly) and, 3 days afterward, misoprostol (800 micrograms, given vaginally). OUTCOME MEASURES: Number of abortions induced within 24 hours and within 10 days of misoprostol administration, number of surgical aspirations conducted because of incomplete abortion, mean amount of bleeding and pain and the number of women who, if faced with the same situation, said they would again choose a drug-induced abortion over a surgical one. RESULTS: Abortion occurred within 24 hours of misoprostol administration among 48 women and within 10 days among 69 women. In total, 89 women had an abortion without surgical aspiration. Of these women, 71 said they would choose a drug-induced abortion if faced with the choice again. CONCLUSION: Abortion induced with methotrexate and misoprostol appears to be a feasible alternative to surgical abortion and deserves further study.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatment of ectopic pregnancy. Obstet Gynecol. 1991 May;77(5):754–757. [PubMed]
  • Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol. 1993 Jun;168(6 Pt 1):1759–1765. [PubMed]
  • Stovall TG, Ling FW, Buster JE. Reproductive performance after methotrexate treatment of ectopic pregnancy. Am J Obstet Gynecol. 1990 Jun;162(6):1620–1624. [PubMed]
  • Peyron R, Aubény E, Targosz V, Silvestre L, Renault M, Elkik F, Leclerc P, Ulmann A, Baulieu EE. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993 May 27;328(21):1509–1513. [PubMed]
  • Thong KJ, Dewar MH, Baird DT. What do women want during medical abortion? Contraception. 1992 Nov;46(5):435–442. [PubMed]
  • Creinin MD, Darney PD. Methotrexate and misoprostol for early abortion. Contraception. 1993 Oct;48(4):339–348. [PubMed]
  • Creinin MD. Methotrexate for abortion at < or = 42 days gestation. Contraception. 1993 Dec;48(6):519–525. [PubMed]
  • Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial. JAMA. 1994 Oct 19;272(15):1190–1195. [PubMed]
  • Creinin MD. Methotrexate and misoprostol for abortion at 57-63 days gestation. Contraception. 1994 Dec;50(6):511–515. [PubMed]
  • Creinin MD, Vittinghoff E, Galbraith S, Klaisle C. A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. Am J Obstet Gynecol. 1995 Nov;173(5):1578–1584. [PubMed]
  • Bachelot A, Cludy L, Spira A. Conditions for choosing between drug-induced and surgical abortions. Contraception. 1992 Jun;45(6):547–559. [PubMed]
  • Henshaw RC, Naji SA, Russell IT, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ. 1993 Sep 18;307(6906):714–717. [PubMed]
  • Urquhart DR, Templeton AA. Psychiatric morbidity and acceptability following medical and surgical methods of induced abortion. Br J Obstet Gynaecol. 1991 Apr;98(4):396–399. [PubMed]
  • Tang GW. A pilot study of acceptability of RU486 and ONO 802 in a Chinese population. Contraception. 1991 Nov;44(5):523–532. [PubMed]
  • Doherty P. Medical abortion. BMJ. 1992 Feb 29;304(6826):573. [PubMed]
  • Kidd GM. Medical abortion. BMJ. 1992 May 23;304(6838):1380. [PubMed]
  • Thong KJ, Baird DT. Medical abortion. BMJ. 1992 Jul 18;305(6846):187–188. [PubMed]
  • Milunsky A, Graef JW, Gaynor MF., Jr Methotrexate-induced congenital malformations. J Pediatr. 1968 Jun;72(6):790–795. [PubMed]
  • Powell HR, Ekert H. Methotrexate-induced congenital malformations. Med J Aust. 1971 Nov 20;2(21):1076–1077. [PubMed]
  • Ross GT. Congenital anomalies among children born of mothers receiving chemotherapy for gestational trophoblastic neoplasms. Cancer. 1976 Feb;37(2 Suppl):1043–1047. [PubMed]
  • Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990 Jun;88(6):589–592. [PubMed]
  • Gonzalez CH, Vargas FR, Perez AB, Kim CA, Brunoni D, Marques-Dias MJ, Leone CR, Correa Neto J, Llerena Júnior JC, de Almeida JC. Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet. 1993 Aug 1;47(1):59–64. [PubMed]
  • Schüler L, Ashton PW, Sanseverino MT. Teratogenicity of misoprostol. Lancet. 1992 Feb 15;339(8790):437. [PubMed]